- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06349408
IBI3001 hos deltakere med uoperable, lokalt avanserte eller metastatiske solide svulster
En fase 1/2-studie av IBI3001 hos deltakere med uoperable, lokalt avanserte eller metastatiske solide svulster
This is a Phase 1 multicenter, multi-regional, open-label, first-in-human study of IBI3001 in participants with unresectable, locally advanced or metastatic solid tumors. The purpose of this study is to identify the MTD/RP2D of IBI3001, and to explore the preliminary efficacy of IBI3001.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
Studiesteder
-
-
New South Wales
-
Wollongong, New South Wales, Australia, 2500
- Rekruttering
- Wollongong Hospital
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Rekruttering
- Cancer Research SA
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
-
-
California
-
Los Angeles, California, Forente stater, 90025
- Rekruttering
- START Center for Cancer Research
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
New Jersey
-
East Brunswick, New Jersey, Forente stater, 08816
- Rekruttering
- START Center for Cancer Research
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Texas
-
Dallas, Texas, Forente stater, 75039
- Rekruttering
- NEXT Oncology
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Aktiv, ikke rekrutterende
- Virginia Cancer Specialists
-
-
-
-
Anhui
-
Hefei, Anhui, Kina, 230022
- Rekruttering
- The First Affiliated Hospital of Anhui Medical University
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100021
- Rekruttering
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Beijing, Beijing Municipality, Kina, 100853
- Rekruttering
- Chinese People's Liberation Army General Hospital
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Fujian
-
Fuzhou, Fujian, Kina, 350014
- Rekruttering
- Fujian Cancer Hospital
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Fuzhou, Fujian, Kina, 350005
- Rekruttering
- First Affiliated Hospital, Fujian Medical University
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Guangxi
-
Nanning, Guangxi, Kina, 530021
- Rekruttering
- The Affiliated Tumor Hospital of Guangxi Medical University
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Heilongjiang
-
Harbin, Heilongjiang, Kina, 150081
- Rekruttering
- Harbin Medical University Cancer Hospital
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Henan
-
Anyang, Henan, Kina, 455100
- Rekruttering
- Anyang Cancer Hospital
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Luoyang, Henan, Kina, 471003
- Rekruttering
- The First Affiliated Hospital of Henan University of Science and Technology
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Zhengzhou, Henan, Kina, 450008
- Rekruttering
- Henan Cancer Hospital
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Zhengzhou, Henan, Kina, 450052
- Rekruttering
- The First Affiliated Hospital of Zhengzhou University
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Rekruttering
- Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Hunan
-
Changsha, Hunan, Kina, 410008
- Rekruttering
- Xiangya Hospital, Central South University
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210008
- Rekruttering
- Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Nanjing, Jiangsu, Kina, 210029
- Rekruttering
- Jiangsu Province Hospital (The First Affiliated Hospital of Nanjing Medical University)
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Jiangxi
-
Nanchang, Jiangxi, Kina, 330029
- Rekruttering
- Jiangxi Cancer Hospital
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200120
- Rekruttering
- Shanghai East Hospital, Tongji University School of Medicine
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- Rekruttering
- West China Hospital, Sichuan University
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Chengdu, Sichuan, Kina, 610041
- Rekruttering
- Sichuan Cancer Hospital & Institute
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310022
- Rekruttering
- Zhejiang Cancer Hospital
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
Hangzhou, Zhejiang, Kina, 310003
- Rekruttering
- The First Affiliated Hospital, Zhejiang University School of Medicine
-
Ta kontakt med:
- Fortvita Biologics CT.gov Call Center
- Telefonnummer: 650-370-0985
- E-post: ct.govNotifications@fortvitabio.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Male or female participants ≥ 18 years old;
- Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;
- Has an anticipated life expectancy of ≥ 12 weeks;
- Adequate bone marrow and organ function:
- At least 1 evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. for dose escalation , and 1 measurable lesion for dose expansion.
- Has a documented (histologically- or cytologically-proven), unresectable, locally advanced or metastatic solid tumor that is refractory to or intolerable with standard treatment, or for which no standard treatment is available; participants who refuse standard therapy, or are able to suspend standard therapy without major risks.
Key Exclusion Criteria:
- Progressed or refractory to an ADC that consists of an Exatecan derivative that is a topoisomerase I inhibitor or intolerable with an ADC that consists of Exatecan;
- Plan to receive other antitumor therapy during the study excluding palliative radiotherapy for the purpose of symptom (like pain) relief that must also not have an impact on tumor assessment throughout the study;
- Pyloric obstruction and/or persistent recurrent vomiting (≥ 3 times in 24 hours);
- Gastrointestinal perforation and/or fistula within 6 months prior to first administration of the study drug, and not recovered after surgical treatment;
- Known symptomatic central nervous system (CNS) metastases.
- History of pneumonia requiring corticosteroids therapy, or history of clinically significant lung diseases; Uncontrolled diseases;
- History of endotracheal or gastrointestinal stent implantation;
- Ascites, pleural effusion, or pericardial effusion with symptoms and requiring intervention;
- Esophageal or gastric varices requiring immediate intervention;
- Not eligible to participate in this study at the discretion of the investigator;
- Do not have adequate treatment washout period before study drug administration. -
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Åpen etikett: IBI3001 monoterapi
|
The provisional dose levels are planned to be evaluated, but it is possible for additional and/or intermediate dose levels to be added during the study. IBI3001 is proposed to be administered by intravenous infusion (IV) |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of subjects with adverse events
Tidsramme: 24 months
|
Occurrence and severity of adverse events (AEs), with severity determined by NCI CTCAE v5.0 criteria |
24 months
|
|
Number of subjects with clinically significant changes in physical examination results
Tidsramme: 24 months
|
Clinically significant abnormal physical examination findings reported by the investigator. |
24 months
|
|
Number of subjects with clinically significant changes in vital signs
Tidsramme: 24 months
|
Vital signs including body temperature, pulse, respiratory rate, SpO2 and blood pressure |
24 months
|
|
MTD or RP2D of IBI3001 Number of subjects with dose-limiting toxicities (DLTs)
Tidsramme: 24 months
|
Dose limiting toxicity (DLT) to establish MTD or RP2D |
24 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Plasma concentration (Cmax) of IBI3001
Tidsramme: 24 months
|
Plasma concentration of IBI3001 for single and multiple doses. |
24 months
|
|
Area under the curve (AUC) of IBI3001
Tidsramme: 24 months
|
AUC of IBI3001 for single and multiple doses |
24 months
|
|
Time to maximum concentration (Tmax) of IBI3001
Tidsramme: 24 months
|
Tmax of IBI3001 for single and multiple doses. |
24 months
|
|
Clearance (CL) of IBI3001
Tidsramme: 24 months
|
Clearance of IBI3001 from the plasma |
24 months
|
|
Volume of distribution (V) of IBI3001
Tidsramme: 24 months
|
Apparent volume of distribution of IBI3001 |
24 months
|
|
Half-life (T1/2) of IBI3001
Tidsramme: 24 months
|
T1/2 of IBI3001 for single and multiple doses |
24 months
|
|
Immunogenicity of IBI3001
Tidsramme: 24 months
|
Incidence of anti-drug (IBI3001) antibody |
24 months
|
|
Objective response rate (ORR)
Tidsramme: 24 months
|
ORR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Duration of response (DoR)
Tidsramme: 24 months
|
DoR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Disease control rate (DCR)
Tidsramme: 24 months
|
DCR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Time to response (TTR)
Tidsramme: 24 months
|
TTR as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Progression free survival (PFS)
Tidsramme: 24 months
|
PFS as evaluated per the RECIST v1.1 criteria |
24 months
|
|
Overall survival (OS)
Tidsramme: 24 months
|
Overall survival. |
24 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- CIBI3001A101
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .